Table 1. Change of biochemical variables in serum or urine during the therapy process.

	Characteristics of AKI model in urine or serum				Biochemical variables in urine after therapy			Biochemical variables in serum after therapy
	NAG(U/L)	LZM(U/ml)	Creatine(µM)	UN(mM)	NAG(U/L)	LZM(U/ml)	UN(mM)	NAG(U/L)	Creatine(µM)	UN(mM)
normal group	13.8±2.7	32.7±2.7	21.2±7.7	9.5±2.1	17.4±3.2	34.2±4.2	33.1±3.1	17.9±3.1	19.9±6.7	7.7±2.1
model group	63.1±6.3*	302.4±55.5*	65.2±9.9*	26.5±4.1*	62.7±17.2	406.7±71.4	15.7±5.6	58.3±5.6	78.4±6.5	28.1±4.6
positive drug group					19.3±5.6*	249.1±32.6*	24.3±4.9*	16.3±3.2*	22.1±4.3*	26.3±4.4
muscone group					23.0±5.8*	278.1±66.6*	16.1±4.2	17.8±5.7*	42.2±3.2*	27.3±6.2
BMSCs group					20.1±7.1*	273.5±82.3*	25.1±2.6*	19.7±4.3*	33.2±3.8*	26.4±5.3
combined group					17.8±5.3*	254.2±59.4*	30.8±3.5*#	19.5±5.3*	26.6±4.3*#	28.7±4.8

To assay the characteristics of rat AKI model, NAZ and LAM in urine, as well as creatinine and urea nitrogen (UN) in serum, were detected on day 7. *P<0.05 compared with the normal group. To analyze the therapeutic effect, urine and serum samples of each group were collected from each group on day 15 after animals were sacrificed. The levels of UN, NAZ, and LAM in urine, as well as creatinine, UN, and NAG in serum, were measured. *P<0.05 compared with the model group; #P<0.05 compared with the muscone and BMSC groups.